Efficacy and safety of glucocorticoids therapy for IgA nephropathy: A meta-analysis of randomized controlled trials

American Journal of Nephrology

Volumn 30, Issue 4, 2009, Pages 315-322

  Cheng, Jun ^a   Zhang, Xiaohui ^a   Zhang, Wen ^b   He, Qiang ^a   Tao, Xiaojuan ^b   Chen, Jianghua ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Hangzhou Red Cross Hospital   (China)

Author keywords

Glucocorticoids; IgA nephropathy

Indexed keywords

CILAZAPRIL; CREATININE; DIPYRIDAMOLE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CUSHINGOID SYNDROME; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEARTBURN; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INSOMNIA; KIDNEY FUNCTION; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; REVIEW; SIDE EFFECT; STEROID THERAPY; SWEATING; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

GLOMERULONEPHRITIS, IGA; GLUCOCORTICOIDS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67449116205     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226129     Document Type: Review

References (29)

1. Berger J, Hinglais N: Les depots intercapillaires d'IgA-IgG. J Urol Nephrol 1968; 74: 694-695.
2. D'Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 245: 709-727.
3. Julian BA, Waldo FB, Rifai A, Mestecky J: IgA nephropathy, the most common glomerulonephritis worldwide: a neglected disease in the United States? Am J Med 1988; 84: 129-132.
4. Levy M, Berger J: Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988; 12: 340-347.
5. Schena FP: Immunoglobulin A nephropathy with mild renal lesions: a call in the forest for the physicians and nephrologists. Am J Med 2001; 110: 499-500. (Pubitemid 32452342)
6. Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al: Immunomodulation with low-dose immunoglobulins for moderate IgAN and Henoch-Schonlein purpura. Preliminary results of a prospective uncontrolled trial. Nephron 1995; 69: 327-334.
7. Samuels JA, Strippoli GF, Craig JC, et al: Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2003;CD003965.
8. Barratt J, Feehally J: IgA nephropathy. J Am Soc Nephrol 2005; 16: 2088-2097.
9. Floege J, Eitner F: Present and future therapy options in IgA nephropathy. J Nephrol 2005; 18: 354-361. (Pubitemid 41700096)
10. Juni P, Altman DG, Egger M: Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-46. (Pubitemid 32682008)
11. Schulz KF, Chalmers I, Hayes RJ, et al: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
12. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
13. Palmer BF: Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007; 27: 287-293. (Pubitemid 47177217)
14. Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival end-points. Stat Med 1998; 17: 2815-2834. (Pubitemid 28562978)
15. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
16. Fleiss JL: Analysis of data from multiclinic trials. Control Clin Trials 1986; 7: 267-275.
17. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
18. Lv J, Zhang H, Chen Y, et al: Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J of Kidney Dis. 2009; 53(1):26-32.
19. Hogg RJ, Lee J, Nardelli N, et al: Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006; 1: 467-474.
20. Julian BA, Barker C: Alternate day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Contrib Nephrol 1993; 104: 198-206.
21. Lai KN, Lai FM, Ho CP, Chan KW: Cortico-steroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174-180.
22. Pozzi C, Bolasco PG, Fogazzi GB, et al: Cortico-steroids in IgA nephropathy: a randomized controlled trial. Lancet 1999; 353: 883-887. (Pubitemid 29126876)
23. Katafuchi R, Kiyoshi I, Mizumasa T, Tanaka H, et al: Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003; 41: 972-983. (Pubitemid 36532131)
24. Shoji T, Nakanishi I, Suzuki A, et al: Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 2000; 35: 194-201. (Pubitemid 30070839)
25. Nolin L, Courteau M: Management of IgA nephropathy: evidence-based recommendations. Kidney Int 1999; 70(suppl):S56-S62. (Pubitemid 29268804)
26. Strippoli GF, Manno C, Schena FP: An 'evidence-based' survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis 2003; 41: 1129-1139.
27. Samuels JA, Strippoli GF, Craig JC, et al: Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton) 2004; 9: 177-185. (Pubitemid 39318639)
28. Kawamura T: Treatment of IgA nephropathy: glucocorticoids, tonsillectomy, and mycophenolate mofetil. Contrib Nephrol 2007; 157: 37-43.
29. Navaneethan SD, Viswanathan G, Strippoli GF: Meta-analysis of mycophenolate mofetil in IgA nephropathy. Nephrology (Carlton) 2008; 13: 90.